Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Receivables: 2024-2025

Historic Receivables for ARS Pharmaceuticals (SPRY) over the last 1 years, with Sep 2025 value amounting to $40.7 million.

  • ARS Pharmaceuticals' Receivables rose 4302.16% to $40.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.5 million, marking a year-over-year change of. This contributed to the annual value of $9.4 million for FY2024, which is N/A change from last year.
  • Per ARS Pharmaceuticals' latest filing, its Receivables stood at $40.7 million for Q3 2025, which was up 49.97% from $27.2 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Receivables ranged from a high of $40.7 million in Q3 2025 and a low of $925,000 during Q3 2024.
  • For the 2-year period, ARS Pharmaceuticals' Receivables averaged around $17.7 million, with its median value being $10.3 million (2025).
  • Data for ARS Pharmaceuticals' Receivables shows a peak YoY soared of 4,302.16% (in 2025) over the last 5 years.
  • Over the past 2 years, ARS Pharmaceuticals' Receivables (Quarterly) stood at $9.4 million in 2024, then soared by 4,302.16% to $40.7 million in 2025.
  • Its Receivables stands at $40.7 million for Q3 2025, versus $27.2 million for Q2 2025 and $10.3 million for Q1 2025.